Mycoplasma genitalium (MG) is a cause of urethritis in men and is becoming increasingly recognized for its etiologic role in cervicitis, endometritis, pelvic inflammatory disease, tubal factor infertility, and preterm birth in women. Unfortunately, this bacterium is resistant to cell wall-targeting antibiotics and to many of the antibiotics curretly used to treat primary disease and possible serious reproductive tract disease sequelae. MG infection may persist in humans for months to years in both men and women despite the induction of an inflammatory response and specific antibodies during infection. We and others have hypothesized that this persistence is based on the ability of MG to evade the host immune response by antigenic variation in two of its surface proteins, MgpB and MgpC located in its complex and unique terminal organelle. Supporting this hypothesis, we have shown that variation in mgpB and mgpC, the adjacent genes encoding these proteins, is extensive both in vivo and evolves over time in cervical/vaginal infections. However, up to this point, we have not been able to test this hypothesis by assessing the role of antibodies induced by infection on gene variation and antigenic selection of contemporary and temporally matched patient isolates. Our recent NIH-funded treatment trial for M. genitalium has given us such an opportunity. In this completed trial, M. genitalium infected men were identified and asked to return at three week intervals for three to four visits at which time sera was collected and their M. genitalium strains were cultured and characterized. These experiments are unprecedented because recent clinical isolates, not laboratory-adapted strains will be used in tour study. Thus we propose to 1) characterize the evolution of mgpB sequence variation of at different time points throughout the longitudinal study, 2) correlate the clearance of specific variable sequences in mgpB with the development of antibodies to these sequences in the infected men, and 3) determine if the antibodies to these variant sequences enhance complement-mediated killing of M. genitalium. This study is innovative in its economical use of an extremely valuable and well-characterized set of patient specimens to assess the role of gene variation on persistence of this newly recognized pathogen. This study is significant in that it will reveal, in part, the mechanisms of immune evasion in this newly recognized genital pathogen. The potential impact of our focus on the immunopathogenesis of this understudied bacterium is great in that novel targets for intervention and treatment may be identified.

Public Health Relevance

The proposed studies are focused on Mycoplasma genitalium, a newly recognized genital tract pathogen associated with urethritis in men and cervicitis and infection of the upper genital tract in women. We hypothesize that this organism is able to change the sequences of two of its surface-exposed proteins, allowing it to escape the host's immune response to persist, cause chronic disease, and possible serious upper genital tract sequelae in women. Our study will explore these hypotheses using temporally-matched sera and M. genitalium isolates collected from these men, allowing the assessment of the biologic effects of specific antibodies to these variable proteins.

Agency
National Institute of Health (NIH)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI107402-02
Application #
8721850
Study Section
Clinical Research and Field Studies of Infectious Diseases Study Section (CRFS)
Program Officer
David, Hagit S
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98195